Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05240690 | Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies | unknown | Phase 1 | 27 | Zhou FuxiangOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT04506983 | GPC3-CAR-T Cells for the Hepatocellular Carcinoma | suspended | Phase 1 | 12 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT04811898 | A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment(LNA-i-miR221) | completed | Phase 1 | 17 | Azienda Ospedaliera Universitaria Mater Domini, CatanzaroOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT02947165 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 9 | Jan 31, 2022 | clinicaltrials |
| NCT04233840 | P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 72 | National Taiwan University HospitalOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT02837029 | Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05131763 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | unknown | Phase 1 | 3 | Fudan UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04973098 | Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma | unknown | Phase 1 | 13 | Peking UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT02304289 | Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma(DESPARTH) | terminated | Phase 1 | 2 | University Hospital, GhentOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT02507765 | Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 16 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT00892658 | Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP) | completed | Phase 1 | 24 | University Health Network, TorontoOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT05042336 | The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC | unknown | Phase 1 / Phase 2 | 49 | Sichuan UniversityOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT01126463 | 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas(LIP-RE-I) | completed | Phase 1 | 16 | Center Eugene MarquisOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT03245190 | Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 27 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jun 18, 2021 | clinicaltrials |
| NCT04331743 | A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC | unknown | Phase 1 | 18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jun 16, 2021 | clinicaltrials |
| NCT04926532 | Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma(Toripalimab) | unknown | Phase 1 / Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT02292173 | Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT03203304 | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | terminated | Phase 1 | 14 | University of ChicagoOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT01271504 | E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 102 | Eisai Inc.INDUSTRY | 6 | May 12, 2021 | clinicaltrials |
| NCT02859324 | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 4 | May 11, 2021 | clinicaltrials |
| NCT04843943 | Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Apr 14, 2021 | clinicaltrials |
| NCT02953743 | Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 25 | Eisai Co., Ltd.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT02642913 | Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients | completed | Phase 1 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT04121273 | GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC | unknown | Phase 1 | 20 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03941626 | Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04072679 | Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 50 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01666756 | Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT04665362 | IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC | unknown | Phase 1 | 10 | Liang PengOTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT02572687 | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | completed | Phase 1 | 85 | Eli Lilly and CompanyINDUSTRY | 8 | Jan 20, 2021 | clinicaltrials |
| NCT04677088 | TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation | unknown | Phase 1 | 7 | Xiaoshun HeOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02988440 | Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT00823290 | Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 | 2 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT01264705 | Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer | completed | Phase 1 / Phase 2 | 47 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01835223 | Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 33 | Roswell Park Cancer InstituteOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT03645980 | DKN-01 Inhibition in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 70 | Johannes Gutenberg University MainzOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | withdrawn | Phase 1 | 0 | Jiujiang University Affiliated HospitalOTHER_GOV | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT04550663 | NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors | unknown | Phase 1 | 10 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT03289533 | A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) | completed | Phase 1 | 22 | PfizerINDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04538313 | A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs | unknown | Phase 1 / Phase 2 | 40 | CAR-T (Shanghai) Cell Biotechnology Co., Ltd.NETWORK | 1 | Sep 4, 2020 | clinicaltrials |
| NCT02069145 | Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer | completed | Phase 1 | 10 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 11, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Feb 15, 2022source: clinicaltrials